Related references
Note: Only part of the references are listed.Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study
Bhavana Bhatnagar et al.
LEUKEMIA & LYMPHOMA (2020)
Phase I Clinical Trial of Selinexor in Combination with Daunorubicin and Cytarabine in Previously Untreated Poor-Risk Acute Myeloid Leukemia
Kendra Sweet et al.
CLINICAL CANCER RESEARCH (2020)
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
Ramzi Abboud et al.
HAEMATOLOGICA (2020)
Opposing effects of NPM1wt and NPM1c mutants on AKT signaling in AML
Zhuo Ren et al.
LEUKEMIA (2020)
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou et al.
LEUKEMIA (2020)
Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer
Kevin H. Lin et al.
NATURE GENETICS (2020)
SynergyFinder 2.0: visual analytics of multi-drug combination synergies
Aleksandr Ianevski et al.
NUCLEIC ACIDS RESEARCH (2020)
A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia
Walter Fiedler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial
Nagesh Kalakonda et al.
Lancet Haematology (2020)
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies
Angela Su et al.
CANCER DISCOVERY (2020)
Frontline Selinexor and Chemotherapy Is Highly Active in Older Adults with Acute Myeloid Leukemia (AML)
Timothy S. Pardee et al.
BLOOD (2020)
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies
Melissa A. Fischer et al.
BLOOD ADVANCES (2020)
Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity
Kevin H. Lin et al.
CELL METABOLISM (2019)
Characterisation of P2Y2 receptors in human vascular endothelial cells using AR-C118925XX, a competitive and selective P2Y2 antagonist
Markie O. Muoboghare et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
PTC-bearing mRNA elicits a genetic compensation response via Upf3a and COMPASS components
Zhipeng Ma et al.
NATURE (2019)
Genetic compensation triggered by mutant mRNA degradation
Mohamed A. El-Brolosy et al.
NATURE (2019)
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma
Ajai Chari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis
Li-Peng Hu et al.
CLINICAL CANCER RESEARCH (2019)
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
Weiguo Zhang et al.
HAEMATOLOGICA (2018)
A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia
Amy Y. Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death
Christian Argueta et al.
Oncotarget (2018)
Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial
Weiguo Zhang et al.
HAEMATOLOGICA (2018)
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Lorenzo Brunetti et al.
CANCER CELL (2018)
Evaluating the bromodomain protein BRD1 as a therapeutic target in rheumatoid arthritis
Kerstin Klein et al.
SCIENTIFIC REPORTS (2018)
Extracellular ATP and P2 purinergic signalling in the tumour microenvironment
Francesco Di Virgilio et al.
NATURE REVIEWS CANCER (2018)
KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells
J. Etchin et al.
LEUKEMIA (2017)
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors
Cristina Saura et al.
CANCER DISCOVERY (2017)
The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia
Nina Fenouille et al.
NATURE MEDICINE (2017)
Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens
Traver Hart et al.
G3-GENES GENOMES GENETICS (2017)
Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer
Mariaelena Pierobon et al.
CLINICAL CANCER RESEARCH (2017)
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
Ramiro Garzon et al.
BLOOD (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
Therapeutic targeting of acute myeloid leukemia stem cells
Daniel A. Pollyea et al.
BLOOD (2017)
Biology and relevance of human acute myeloid leukemia stem cells
Daniel Thomas et al.
BLOOD (2017)
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells
Yoko Tabe et al.
CANCER RESEARCH (2017)
Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice
J. Etchin et al.
LEUKEMIA (2016)
XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus
Parvathi Ranganathan et al.
CLINICAL CANCER RESEARCH (2016)
XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer
Jimi Kim et al.
NATURE (2016)
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update
Maxim V. Kuleshov et al.
NUCLEIC ACIDS RESEARCH (2016)
Importins and exportins as therapeutic targets in cancer
Amit Mahipal et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets
A. Maiga et al.
BLOOD CANCER JOURNAL (2016)
Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia
Parvathi Ranganathan et al.
BLOOD (2015)
Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds
Marsha Crochiere et al.
BMC CANCER (2015)
A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning
Koray Kirli et al.
ELIFE (2015)
Longitudinal tracking of single live cancer cells to understand cell cycle effects of the nuclear export inhibitor, selinexor
Joshua M. Marcus et al.
SCIENTIFIC REPORTS (2015)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
Clinical translation of nuclear export inhibitors in cancer
William T. Senapedis et al.
SEMINARS IN CANCER BIOLOGY (2014)
Promising SINEs for Embargoing Nuclear-Cytoplasmic Export as an Anticancer Strategy
David S. P. Tan et al.
CANCER DISCOVERY (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
Kensuke Kojima et al.
BLOOD (2013)
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Edward Y. Chen et al.
BMC BIOINFORMATICS (2013)
Identification of CRM1-dependent Nuclear Export Cargos Using Quantitative Mass Spectrometry
Ketan Thakar et al.
MOLECULAR & CELLULAR PROTEOMICS (2013)
Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells
J. Etchin et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia
Parvathi Ranganathan et al.
BLOOD (2012)
The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle
Shauna A. Henley et al.
CELL DIVISION (2012)
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome
Bas J. Wouters et al.
BLOOD (2009)
Single-vector inducible lentiviral RNAi system for oncology target validation
Dmitri Wiederschain et al.
CELL CYCLE (2009)
The Karyopherin proteins, Crm1 and Karyopherin β1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation
Pauline J. Van der Watt et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays
Yifang Hu et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications
B. Falini et al.
LEUKEMIA (2009)
AKT1 Inhibits Homologous Recombination by Inducing Cytoplasmic Retention of BRCA1 and RAD51
Isabelle Plo et al.
CANCER RESEARCH (2008)
PTEN-deficient cancers depend on PIK3CB
Susan Wee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants
Niccolo Bolli et al.
CANCER RESEARCH (2007)
Gβγs and the Ras binding domain of p110γ are both important regulators of PI(3)Kγ signalling in neutrophils
Sabine Suire et al.
NATURE CELL BIOLOGY (2006)
Crm1 is a mitotic effector of Ran-GTP in somatic cells
A Arnaoutov et al.
NATURE CELL BIOLOGY (2005)
DNA damage induces p53-dependent BRCA1 nuclear export
ZH Feng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Control of apoptosis by p53
JS Fridman et al.
ONCOGENE (2003)
The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer
K Vermeulen et al.
CELL PROLIFERATION (2003)
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
I Shin et al.
NATURE MEDICINE (2002)
PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest
J Liang et al.
NATURE MEDICINE (2002)
Cytoplasmic-nuclear shuttling of FKBP12-rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation
JE Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase γ
ME Pacold et al.
CELL (2000)
Phosphorylation of phosducin and phosducin-like protein by G protein-coupled receptor kinase 2
A Ruiz-Gómez et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
